Key result
Olmesartan significantly attenuated increases in aspartate aminotransferase, activation of hepatic stellate cells, oxidative stress, and liver fibrosis in a rat model of nonalcoholic steatohepatitis.
Why the study?
Does olmesartan reduce biochemical, histologic, and antioxidant measures of disease activity in a rat model of nonalcoholic steatohepatitis?
Population
Methionine-choline-deficient rat model of nonalcoholic steatohepatitis (NASH)
Design
Preclinical
Authors
Loading...
Hypothesis-generating for ARBs in NASH fibrosis; leaves open translation to human disease.
Does olmesartan reduce biochemical, histologic, and antioxidant measures of disease activity in a rat model of nonalcoholic steatohepatitis?
In a rat model of NASH, the ARB olmesartan significantly reduced hepatic fibrosis, oxidative stress, and stellate cell activation, suggesting a potential therapeutic role.
Hirose et al. (2007) studied Nonalcoholic steatohepatitis (NASH). Olmesartan (angiotensin II type 1 receptor blocker) was evaluated on Biochemical, histologic, and antioxidant measures of disease activity. Olmesartan significantly attenuated increases in aspartate aminotransferase, activation of hepatic stellate cells, oxidative stress, and liver fibrosis in a rat model of nonalcoholic steatohepatitis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: